SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China

NEXT STORY
Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Technology
PREV STORY
Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunicum AB: Invitation to Investor Events

Press Release 21 March 2018 Immunicum AB: Invitation to Investor Events Immunicum AB (publ; ...

author_avatar
NASDAQ Market News

RedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations

Key Highlights: Top-line results from confirmatory Phase III study with TALICIA® for H. pylori ...

author_avatar
NASDAQ Market News

Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products

SANTA CLARA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary ...

author_avatar
NASDAQ Market News